These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 4852201)

  • 21. [Reduction of plasma concentrations of phenylbutazone and oxyphenbutazone in smokers].
    Ollagnier M; Queneau P; Latour JF; Brazier JL; Decousus H; Faucon G
    Therapie; 1982; 37(5):549-56. PubMed ID: 7179323
    [No Abstract]   [Full Text] [Related]  

  • 22. Specimen handling in an HPLC determination of phenylbutazone and its major metabolites in plasma, avoiding degradation of the compounds.
    Franssen MJ; Tan Y; Freij I; Van Ginneken CA; Gribnau FW
    Pharm Weekbl Sci; 1986 Aug; 8(4):229-33. PubMed ID: 3763367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individual differences in the plasma half-lives of lipid soluble drugs in man.
    Davies DS; Thorgeirsson SS
    Acta Pharmacol Toxicol (Copenh); 1971; 29 Suppl 3():181-90. PubMed ID: 5316400
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma and serum concentrations of phenylbutazone and oxyphenbutazone in racing Thoroughbreds 24 hours after treatment with various dosage regimens.
    Soma LR; Sams R; Duer W; Tobin T; Woodward C; McDonald J
    Am J Vet Res; 1985 Apr; 46(4):932-8. PubMed ID: 4014842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLC determination of plasma levels of warfarin.
    Midha KK; McGilveray IJ; Cooper JK
    J Pharm Sci; 1974 Nov; 63(11):1725-9. PubMed ID: 4427231
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies of the interaction of phenylbutazone, oxyphenbutazone and methandrostenolone in man.
    Hvidberg EF; Dayton PG; Read JM; Wilson CH
    Proc Soc Exp Biol Med; 1968 Nov; 129(2):438-43. PubMed ID: 5696765
    [No Abstract]   [Full Text] [Related]  

  • 27. Plasma half-life of phenylbutazone in patients with impaired liver function.
    Hvidberg EF; Andreasen PB; Ranek L
    Clin Pharmacol Ther; 1974 Feb; 15(2):171-7. PubMed ID: 4855829
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin.
    Abd Elbary A; Vallner JJ; Whitworth CW
    J Pharm Sci; 1982 Feb; 71(2):241-4. PubMed ID: 7062254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GLC determination of plasma concentrations of gamma-oxo metabolite of phenylbutazone.
    Midha KK; McGilveray IJ; Cooper JK
    J Pharm Sci; 1978 Feb; 67(2):279-81. PubMed ID: 621659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenylbutazone and its metabolites in plasma and urine of thoroughbred horses: population distributions and effects of urinary pH.
    Houston T; Chay S; Woods WE; Combs G; Kamerling S; Blake JW; Edmundson AG; Vessiney R; Tobin T
    J Vet Pharmacol Ther; 1985 Jun; 8(2):136-49. PubMed ID: 4020945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absorption of phenylbutazone from a paste formulation administered orally to the horse.
    Lees P; Higgins AJ; Mawhinney IC; Reid DS
    Res Vet Sci; 1986 Sep; 41(2):200-6. PubMed ID: 3775111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct injection HPLC method for the determination of phenylbutazone and oxyphenylbutazone in serum using a semipermeable surface column.
    Haque A; Stewart JT
    J Pharm Biomed Anal; 1997 Oct; 16(2):287-93. PubMed ID: 9408846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of therapeutic agents in blood.
    Marks V; Lindup WE; Baylis EM
    Adv Clin Chem; 1973; 16():47-109. PubMed ID: 4589494
    [No Abstract]   [Full Text] [Related]  

  • 34. Simultaneous determination of hydrocortisone, dexamethasone, indomethacin, phenylbutazone and oxyphenbutazone in equine serum by high-performance liquid chromatography.
    Grippa E; Santini L; Castellano G; Gatto MT; Leone MG; Saso L
    J Chromatogr B Biomed Sci Appl; 2000 Jan; 738(1):17-25. PubMed ID: 10778922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition and oxidative metabolism of phenylbutazone in man.
    Aarbakke J; Bakke OM; Milde EJ; Davies DS
    Eur J Clin Pharmacol; 1977; 11(5):359-66. PubMed ID: 880975
    [No Abstract]   [Full Text] [Related]  

  • 36. Circadian changes in carrageenin-induced edema: the anti-inflammatory effect and bioavailability of phenylbutazone in rats.
    Loubaris N; Michel A; Cros G; Serrano JJ; Katz S; Boucard M
    Life Sci; 1984 Jun; 34(24):2379-84. PubMed ID: 6727571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proton magnetic resonance spectroscopic method for determination of phenylbutazone and oxyphenbutazone in tablets.
    Husain S; Kifayatullah M; Rao RN
    J Assoc Off Anal Chem; 1988; 71(3):525-7. PubMed ID: 3391955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLC determination of phenylbutazone in human plasma.
    Sioufi A; Caudal F; Marfil F
    J Pharm Sci; 1978 Feb; 67(2):243-5. PubMed ID: 621647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of dietary portein on the disposition and metabolism of phenylbutazone in rats.
    Varma DR
    Can J Physiol Pharmacol; 1980 Mar; 58(3):231-6. PubMed ID: 7378926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug interactions in the horse: effects of chloramphenicol, quinidine, and oxyphenbutazone on phenylbutazone metabolism.
    Tobin T; Blake JW; Valentine R
    Am J Vet Res; 1977 Jan; 38(1):123-7. PubMed ID: 835859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.